[Lorne Cancer Conference 2019] Validating the Immuno-Oncology Potential of Candidates and Combinations Using Human in vitro BioMAP® Oncology Models

[Lorne Cancer Conference 2019] Validating the Immuno-Oncology Potential of Candidates and Combinations Using Human in vitro BioMAP® Oncology Models
File Name/Number:
Lorne Cancer Conference 2019

Year:
2019

To date, a total of 26 immune oncology (I-O) therapies have been approved, including six immune checkpoint inhibitors targeting 18 different cancer types. Compelling clinical reports have propelled this anti-cancer strategy to a high priority focus of multiple drug pipelines. However, while these I-O drugs have led to increased survival, current reports indicate that only 25% to 30% of patients, and as low as 10% for some cancers, have achieved good objective responses rates. Thus, there is a clear need for more, better and safer I-O therapies to be developed. Currently, more than 3,000 candidates aimed at over 300 targets are in pre-clinical or clinical development worldwide. While this indicates an enormous investment of resources, it also illustrates significant duplication of efforts. Innovative approaches are needed to identify first-in-class and best-in-class therapeutic strategies involving both monotherapies and combination approaches.